Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.
Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.
However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.
This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
Location: France, Ile-de-France, Paris
Employees: 11-50
Total raised: $30.459246M
Founded date: 2013
Investors 4
Date | Name | Website |
- | Newton Bio... | newtonbioc... |
- | Karista Ve... | karista.vc |
- | Agoranov | agoranov.c... |
- | GO Capital... | gocapital.... |
Funding Rounds 5
Date | Series | Amount | Investors | Deal News |
07.11.2019 | Series B | $7.749106M | - | finsmes.co... |
18.10.2018 | Series B | $17.524749... | - | finsmes.co... |
08.01.2018 | - | $2.034911M | - | finsmes.co... |
07.02.2017 | - | $1.601722M | - | finsmes.co... |
11.07.2016 | - | $1.548758M | - | finsmes.co... |
Mentions in press and media 12
Date | Title | Description | Source |
02.09.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Auto... | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates wi... | aithority.... |
01.09.2023 | ACTIMIS Post-hoc Results on Imaging Stroke Data Using Artifi... | Acticor Biotech, a clinical stage biopharmaceutical company developing glenzocimab, an innovative dr... | aithority.... |
12.04.2023 | Startup Showcase: Acticor Biotech – Innovating Stroke Treatm... | Looking for innovative solutions to treat ischemic stroke? Look no further than Acticor Biotech, a b... | eustartup.... |
12.01.2022 | Acticor Biotech SAS : Inside Information / Other news releas... | PRESS RELEASE Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvr... | marketscre... |
04.11.2021 | Acticor Biotech lists on Euronext Growth Paris | 5th listing of a biotech company on Euronext Paris in 2021. Euronext today congratulates Acticor Bi... | marketscre... |
06.11.2019 | Acticor Biotech Raises Additional €7M; Closes Series B At €2... | Acticor Biotech, a Paris, France-based clinical stage biotechnology company involved in the acute ph... | finsmes.co... |
18.10.2018 | Acticor Biotech Raises €15.3M In Series B Financing | Acticor Biotech, a Paris, France-based clinical stage biotechnology company involved in the acute ph... | finsmes.co... |
18.10.2018 | Term Sheet — Thursday, October 18 | 5 Qs WITH A DEALMAKER Founders Fund partner Cyan Banister says capitalism saved her life. Paid Con... | fortune.co... |
08.01.2018 | Acticor Biotech Closes €1.7M Equity Financing | Acticor Biotech, a Paris, France-based clinical stage biotechnology company involved in the acute ph... | finsmes.co... |
05.01.2018 | Term Sheet — Friday, January 5 | THE BILLIONAIRE CLUB Happy Friday, Term Sheet readers! Paid Content Securing the enterprise withou... | fortune.co... |
Show more